Spots Global Cancer Trial Database for adult acute promyelocytic leukemia (m3)
Every month we try and update this database with for adult acute promyelocytic leukemia (m3) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT00062075 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Recurrent Adult... | romidepsin | 18 Years - | National Cancer Institute (NCI) | |
| Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia | NCT00008697 | Leukemia | arsenic trioxid... | - | Washington University School of Medicine | |
| Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia | NCT00002588 | Leukemia | etoposide topotecan hydro... | 18 Years - | Case Comprehensive Cancer Center | |
| Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission | NCT00002768 | Leukemia | filgrastim busulfan cytarabine etoposide methotrexate peripheral bloo... | 15 Years - 69 Years | Alliance for Clinical Trials in Oncology | |
| Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia | NCT00528450 | Leukemia | arsenic trioxid... idarubicin tretinoin | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia | NCT00006213 | Adult Acute Pro... Blastic Phase C... Childhood Myelo... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... | BMS-214662 pharmacological... laboratory biom... | 15 Years - | National Cancer Institute (NCI) | |
| Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia | NCT00016159 | Leukemia | filgrastim lintuzumab arsenic trioxid... idarubicin tretinoin | - | Memorial Sloan Kettering Cancer Center | |
| Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia | NCT00005962 | Leukemia | sargramostim cyclophosphamid... cytarabine gemtuzumab ozog... liposomal dauno... topotecan hydro... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome | NCT00002547 | Leukemia Myelodysplastic... | busulfan cyclophosphamid... cyclosporine cytarabine methotrexate allogeneic bone... syngeneic bone ... | - 60 Years | Barbara Ann Karmanos Cancer Institute | |
| Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia | NCT00002658 | Leukemia Neutropenia | filgrastim amsacrine cyclophosphamid... cytarabine daunorubicin hy... etoposide idarubicin mitoxantrone hy... thioguanine tretinoin allogeneic bone... autologous bone... peripheral bloo... radiation thera... | 15 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission | NCT00454168 | Leukemia | PR1 leukemia pe... sargramostim placebo | 18 Years - | National Cancer Institute (NCI) | |
| BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia | NCT00006213 | Adult Acute Pro... Blastic Phase C... Childhood Myelo... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... | BMS-214662 pharmacological... laboratory biom... | 15 Years - | National Cancer Institute (NCI) | |
| Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia | NCT00005962 | Leukemia | sargramostim cyclophosphamid... cytarabine gemtuzumab ozog... liposomal dauno... topotecan hydro... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| flt3L in Treating Patients With Acute Myeloid Leukemia | NCT00006223 | Leukemia | recombinant flt... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia | NCT00276601 | Leukemia | arsenic trioxid... cytarabine daunorubicin hy... mercaptopurine methotrexate tretinoin | 5 Years - 74 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia | NCT00276601 | Leukemia | arsenic trioxid... cytarabine daunorubicin hy... mercaptopurine methotrexate tretinoin | 5 Years - 74 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia | NCT00003934 | Adult Acute Mye... Adult Acute Pro... Childhood Acute... Untreated Adult... Untreated Child... | tretinoin daunorubicin hy... cytarabine mercaptopurine methotrexate arsenic trioxid... | - | National Cancer Institute (NCI) | |
| Vorinostat in Treating Patients With Acute Myeloid Leukemia | NCT00305773 | Adult Acute Ery... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Recurrent Adult... Refractory Cyto... Secondary Acute... Untreated Adult... | vorinostat vorinostat | 18 Years - | National Cancer Institute (NCI) | |
| Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | NCT00053144 | Leukemia | cytarabine irinotecan hydr... | 15 Years - | Roswell Park Cancer Institute | |
| High-Dose Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia in Remission | NCT00002567 | Bone Marrow Abl... Leukemia | filgrastim etoposide peripheral bloo... low-LET electro... low-LET photon ... | 16 Years - 65 Years | Memorial Sloan Kettering Cancer Center | |
| S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia | NCT00492856 | Leukemia | mercaptopurine methotrexate tretinoin | 18 Years - 120 Years | SWOG Cancer Research Network | |
| High-Dose Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia in Remission | NCT00002567 | Bone Marrow Abl... Leukemia | filgrastim etoposide peripheral bloo... low-LET electro... low-LET photon ... | 16 Years - 65 Years | Memorial Sloan Kettering Cancer Center | |
| Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | NCT00053144 | Leukemia | cytarabine irinotecan hydr... | 15 Years - | Roswell Park Cancer Institute | |
| SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes | NCT00098826 | Acute Undiffere... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Blastic Phase C... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo... Untreated Adult... | ispinesib laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission | NCT00002609 | Leukemia | lintuzumab cytarabine idarubicin | 12 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia | NCT00002701 | Leukemia | busulfan cyclophosphamid... cytarabine etoposide idarubicin mercaptopurine methotrexate mitoxantrone hy... thioguanine tretinoin allogeneic bone... autologous bone... radiation thera... | 16 Years - 74 Years | National Cancer Institute (NCI) | |
| Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia | NCT01548911 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Recurrent Adult... | gemtuzumab ozog... laboratory biom... | 18 Years - | Wake Forest University Health Sciences | |
| Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome | NCT00005593 | Leukemia Myelodysplastic... | carboplatin fludarabine pho... topotecan hydro... | 12 Years - | Case Comprehensive Cancer Center | |
| Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia | NCT01869803 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Childhood Acute... Recurrent Adult... Recurrent Child... | gemtuzumab ozog... laboratory biom... | 18 Years - | Wake Forest University Health Sciences | |
| Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia | NCT00016159 | Leukemia | filgrastim lintuzumab arsenic trioxid... idarubicin tretinoin | - | Memorial Sloan Kettering Cancer Center | |
| Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia | NCT00245115 | Leukemia | filgrastim busulfan cyclophosphamid... in vitro-treate... in vitro-treate... | - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia | NCT01031368 | Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Recurrent Adult... Untreated Adult... | cytarabine clofarabine filgrastim Ex-vivo expande... laboratory biom... | 18 Years - 70 Years | Nohla Therapeutics, Inc. | |
| Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT00062075 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Recurrent Adult... | romidepsin | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia | NCT00002701 | Leukemia | busulfan cyclophosphamid... cytarabine etoposide idarubicin mercaptopurine methotrexate mitoxantrone hy... thioguanine tretinoin allogeneic bone... autologous bone... radiation thera... | 16 Years - 74 Years | National Cancer Institute (NCI) | |
| Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT00602225 | Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Recurrent Adult... | clofarabine cytarabine filgrastim | 18 Years - 70 Years | University of Washington | |
| Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia | NCT01869803 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Childhood Acute... Recurrent Adult... Recurrent Child... | gemtuzumab ozog... laboratory biom... | 18 Years - | Wake Forest University Health Sciences | |
| R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia | NCT00004009 | Leukemia | tipifarnib | 18 Years - 120 Years | University of Maryland, Baltimore | |
| Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia | NCT00276601 | Leukemia | arsenic trioxid... cytarabine daunorubicin hy... mercaptopurine methotrexate tretinoin | 5 Years - 74 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome | NCT00005593 | Leukemia Myelodysplastic... | carboplatin fludarabine pho... topotecan hydro... | 12 Years - | Case Comprehensive Cancer Center | |
| Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia | NCT00002701 | Leukemia | busulfan cyclophosphamid... cytarabine etoposide idarubicin mercaptopurine methotrexate mitoxantrone hy... thioguanine tretinoin allogeneic bone... autologous bone... radiation thera... | 16 Years - 74 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia | NCT00002658 | Leukemia Neutropenia | filgrastim amsacrine cyclophosphamid... cytarabine daunorubicin hy... etoposide idarubicin mitoxantrone hy... thioguanine tretinoin allogeneic bone... autologous bone... peripheral bloo... radiation thera... | 15 Years - | National Cancer Institute (NCI) | |
| Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia | NCT00003934 | Adult Acute Mye... Adult Acute Pro... Childhood Acute... Untreated Adult... Untreated Child... | tretinoin daunorubicin hy... cytarabine mercaptopurine methotrexate arsenic trioxid... | - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
